"It did occur to me that the current yearly growth in procedures would not be growing as fast if our product becomes the market leader "
The YoY growth is driven by FDA approving use of TAVR in younger patient thus opening up the demographics rather than valve in valve replacement
CEO presentation - one of the best I have seen., page-25
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.30 |
Change
0.300(1.67%) |
Mkt cap ! $351.7M | |||
| Open | High | Low | Value | Volume |
| $18.25 | $18.30 | $18.01 | $12.33K | 679 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $18.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.30 | 247 | 2 |
View Market Depth
| Last trade - 14.56pm 04/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |